Details of the Drug

General Information of Drug (ID: DM5DWMU)

Drug Name
Rimantadine
Synonyms
Remantadine; Riamantadine; Rimant; Rimantadina; Rimantadinum; Enamine_005755; Alpha-Methyladamantanemethylamine; Flumadine (TN); Rimantadina [INN-Spanish]; Rimantadine (INN); Rimantadine [INN:BAN]; Rimantadinum [INN-Latin]; Alpha-Methyl-1-adamantanemethylamine; Rimant & .alpha. IFN; Rimantidine & .alpha.IFN; Tricyclo(3.3.1.1^3,7)decane-1-methanamine, .alpha.-methyl-& IFN.alpha; 1-(1-Adamantyl)ethanamine; 1-(1-Adamantyl)ethylamin; 1-(1-adamantyl)-ethylamine; 1-(1-adamantyl)ethylamine; 1-(adamantan-1-yl)ethan-1-amine; 1-(tricyclo[3.3.1.1~3,7~]dec-1-yl)ethanamine; 1-Adamantan-1-yl-ethylamine; 1-Adamantan-1-ylethylamine; 1-tricyclo[3.3.1.1~3,7~]dec-1-ylethanamine
Indication
Disease Entry ICD 11 Status REF
Influenza A virus infection 1E30 Approved [1]
Influenza virus infection 1E30-1E32 Approved [2]
Severe acute respiratory syndrome (SARS) 1D65 Investigative [3]
Therapeutic Class
Antiviral Agents
Affected Organisms
Human Influenza A Virus
ATC Code
J05AC02: Rimantadine
J05AC: Cyclic amines
J05A: DIRECT ACTING ANTIVIRALS
J05: ANTIVIRALS FOR SYSTEMIC USE
J: ANTIINFECTIVES FOR SYSTEMIC USE
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 179.3
Logarithm of the Partition Coefficient (xlogp) 2.6
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Elimination
20% of drug is excreted from urine in the unchanged form [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 15.934 micromolar/kg/day [5]
Water Solubility
The ability of drug to dissolve in water is measured as 50 mg/mL [4]
Chemical Identifiers
Formula
C12H21N
IUPAC Name
1-(1-adamantyl)ethanamine
Canonical SMILES
CC(C12CC3CC(C1)CC(C3)C2)N
InChI
InChI=1S/C12H21N/c1-8(13)12-5-9-2-10(6-12)4-11(3-9)7-12/h8-11H,2-7,13H2,1H3
InChIKey
UBCHPRBFMUDMNC-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5071
ChEBI ID
CHEBI:94440
CAS Number
13392-28-4
UNII
0T2EF4JQTU
DrugBank ID
DB00478
TTD ID
D0TQ1G
VARIDT ID
DR00832
INTEDE ID
DR2305
ACDINA ID
D00596
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Influenza M2 protein (Influ M) TTXT3PU M2_I34A1 Inhibitor [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Rimantadine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Rimantadine and Polyethylene glycol. Irritable bowel syndrome [DD91] [7]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Rimantadine and Bupropion. Nicotine use disorder [6C4A] [8]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sunset yellow FCF E00255 17730 Colorant
Hypromellose E00634 Not Available Coating agent
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Rimantadine 100 mg tablet 100 mg Oral Tablet Oral
Rimantadine Hydrochloride 100mg tablet 100mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019649.
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 076132.
3 In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol. 2004 Sep;31(1):69-75. doi: 10.1016/j.jcv.2004.03.003.
4 BDDCS applied to over 900 drugs
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Antiviral resistance of influenza A (H3N2) strains isolated in northern Greece between 2004 and 2007. Euro Surveill. 2009 Jan 29;14(4). pii: 19104.
7 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
8 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.